JP2011520847A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520847A5
JP2011520847A5 JP2011508945A JP2011508945A JP2011520847A5 JP 2011520847 A5 JP2011520847 A5 JP 2011520847A5 JP 2011508945 A JP2011508945 A JP 2011508945A JP 2011508945 A JP2011508945 A JP 2011508945A JP 2011520847 A5 JP2011520847 A5 JP 2011520847A5
Authority
JP
Japan
Prior art keywords
ethoxy
xaa
acetyl
amino
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011508945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520847A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/055989 external-priority patent/WO2009138511A1/en
Publication of JP2011520847A publication Critical patent/JP2011520847A/ja
Publication of JP2011520847A5 publication Critical patent/JP2011520847A5/ja
Withdrawn legal-status Critical Current

Links

JP2011508945A 2008-05-16 2009-05-18 遅効型y2及び/又はy4レセプターアゴニスト Withdrawn JP2011520847A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08156360 2008-05-16
EP08156360.3 2008-05-16
EP09154461.9 2009-03-05
EP09154461 2009-03-05
PCT/EP2009/055989 WO2009138511A1 (en) 2008-05-16 2009-05-18 Long-acting y2 and/or y4 receptor agonists

Publications (2)

Publication Number Publication Date
JP2011520847A JP2011520847A (ja) 2011-07-21
JP2011520847A5 true JP2011520847A5 (enExample) 2012-07-05

Family

ID=40934036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508945A Withdrawn JP2011520847A (ja) 2008-05-16 2009-05-18 遅効型y2及び/又はy4レセプターアゴニスト

Country Status (12)

Country Link
US (1) US20110275559A1 (enExample)
EP (1) EP2279204A1 (enExample)
JP (1) JP2011520847A (enExample)
KR (1) KR20110017874A (enExample)
CN (1) CN102027007A (enExample)
AU (1) AU2009248041B2 (enExample)
BR (1) BRPI0912615A2 (enExample)
CA (1) CA2723855A1 (enExample)
IL (1) IL208836A0 (enExample)
MX (1) MX2010011845A (enExample)
RU (1) RU2504550C2 (enExample)
WO (1) WO2009138511A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2450374B9 (en) 2009-07-02 2016-11-23 Takeda Pharmaceutical Company Limited Peptide and use thereof
JP2013505221A (ja) * 2009-09-18 2013-02-14 ノヴォ ノルディスク アー/エス 長時間作用性y2受容体アゴニスト
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2600887A4 (en) 2010-07-09 2014-01-22 Amylin Pharmaceuticals Llc MICROCRYSTALLINE Y RECEPTOR AGONISTS
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
EP2842965A1 (en) 2013-09-03 2015-03-04 Gubra ApS Neuromedin U analogs comprising serum albumin binding amino acid residue
WO2015073878A1 (en) * 2013-11-15 2015-05-21 Ur Diet, Llc Real-time satiety biofeedback
HRP20191036T1 (hr) * 2013-11-15 2019-09-06 Novo Nordisk A/S Selektivni spojevi pyy i njihova upotreba
US9085637B2 (en) 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
EP3094391B1 (en) 2014-01-17 2024-11-20 Repligen Corporation Sterilizing chromatography columns
US20240100450A9 (en) * 2014-01-17 2024-03-28 Repligen Corporation Sterilizing chromatography columns
CN111620940A (zh) * 2014-05-21 2020-09-04 哈佛大学的校长及成员们 Ras抑制肽和其用途
TWI694082B (zh) * 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性pyy化合物及其用途
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
TW202535916A (zh) 2018-11-01 2025-09-16 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
GB201908426D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Appetite suppressing compounds
MX2022013024A (es) * 2020-04-17 2023-03-15 I2O Therapeutics Inc Analogos del peptido tirosina tirosina (pyy) de accion prolongada y metodos de uso de los mismos.
CA3215858A1 (en) 2021-04-27 2022-11-03 Zhenhuan ZHENG Combination of bitter receptor agonist and gut-signaling compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2275207C2 (ru) * 2000-12-14 2006-04-27 Амилин Фармасьютикалз, Инк. Способ снижения доступности питательного вещества, способ подавления аппетита
TW200526254A (en) * 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
US8603969B2 (en) * 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
MXPA06010345A (es) * 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y4 para intervenciones terapeuticas.
MXPA06015049A (es) * 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
WO2007009894A2 (en) * 2005-07-18 2007-01-25 Novo Nordisk A/S Peptides for use in the treatment of obesity

Similar Documents

Publication Publication Date Title
JP2011520847A5 (enExample)
RU2504550C2 (ru) Длительно действующие агонисты рецепторов y2 и(или) y4
AU2014241743B2 (en) Insulin-incretin conjugates
JP2010538049A5 (enExample)
CN114901680B (zh) 长效glp-1化合物
JP5476304B2 (ja) グルカゴン様ペプチド−1誘導体及びそれらの医薬用途
CN114901682B (zh) 胰岛素衍生物
TWI783244B (zh) 升糖素及glp-1共激動劑化合物
JP2013543497A5 (enExample)
JP6108659B2 (ja) 代謝疾患および肥満の治療のためのgipに基づいた混合アゴニスト
US9657079B2 (en) Truncated GLP-1 derivatives and their therapeutical use
JP2016512213A5 (enExample)
HRP20140616T1 (hr) Peptidni analog oksintomodulina
JP2014502252A5 (enExample)
Wu et al. Optimization of protein and peptide drugs based on the mechanisms of kidney clearance
CN108271356A (zh) 肠降血糖素-胰岛素缀合物
US20130096055A1 (en) Long-acting y2 receptor agonists
JP2014521594A5 (enExample)
JP2008533105A5 (enExample)
US9499600B2 (en) Long-acting single-chain insulin analogues
CN107108716A (zh) 双相性单链胰岛素类似物
WO2012050923A2 (en) Engineered polypeptides having enhanced duration of action
WO2010111617A4 (en) Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
EP1945790A2 (en) Vasoactive intestinal polypeptide pharmaceuticals
JPWO2021136303A5 (enExample)